business

Novo Nordisk (NVO) lifts 2026 outlook as obesity drug demand remains strong

Yahoo Finance · May 6, 2026, 10:35 AM · Also reported by 4 other sources

Read full story on Yahoo Finance → More top stories

Also covered by

Investing.com Novo Nordisk lifts 2026 outlook as Wegovy drives growth; shares surge Financial Times Novo Nordisk lifts forecasts after strong demand for Wegovy weight-loss pill Bloomberg Tech Uber Delivers Upbeat Outlook in Sign of Strong US Demand MarketWatch Novo Nordisk says the Wegovy pill saw the fastest take-up in weight-loss drug history.

Aggregated and edited by the Scoop newsroom. We surface news from Yahoo Finance alongside other reporting so you can compare coverage in one place. Editorial policy · Corrections · About Scoop

Novo Nordisk (NVO) lifts 2026 outlook as obesity drug demand remains strong

Also covered by

More in business